Lopinavir/ritonavir superior choice for ART-experienced patients
- PDF / 142,499 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 17 Downloads / 163 Views
Lifetime benefits (QALMs) 5-year cost savings ($US) 10-year cost-savings ($US) Lifetime cost per QALYa ($US) a
Capsules
Tablets
4.6 12 284 14 117 Dominant
5.6 10 411 11 427 Dominant
quality-adjusted life-year
Lopinavir/ritonavir capsule recipients would gain 4.6 quality-adjusted life-months (QALMs) compared with atazanavir plus ritonavir recipients; this benefit would increase to 5.6 QALMs with the use of lopinavir/ ritonavir tablets. Over the first 5 years of treatment, lopinavir/ritonavir capsules would provide total healthcare cost savings of $US12 284 compared with the atazanavir plus ritonavir regimen; over 10 years of treatment, the savings increased to $US14 117. Despite the additional costs of longer survival incurred by lopinavir/ritonavir recipients, lifetime savings of $US3600 may be expected with this regimen. * one of the researchers was affiliated with Abbott Laboratories ** Costs (2005 values) included direct costs only and were calculated from a healthcare system perspective. Simpson KN, et al. Economic and clinical impact of using a protease inhibitor regimen containing atazanavir + ritonavir vs. lopinavir/ritonavir in antiretroviral experienced patients: modeling the lifetime impacts of the 48 week results from BMS AI424-045. 16th International AIDS Conference - Volume 1 (Suppl.): 801044993 308-309 (plus poster) abstr. TUPE0072, 13 Aug 2006
1173-5503/10/0514-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 21 Oct 2006 No. 514
1
Data Loading...
